Press Detail

/
PRESS RELEASE

Biotest AG's Supervisory Board extends the term of CEO Prof. Schulz and appoints Dr. Floß to the Board of Management

Dreieich, January 9, 2013: Today the Supervisory Board of Biotest AG extended the term of CEO Prof. Dr. Gregor Schulz till December 31, 2014. Prof. Schulz manages the Biotest Group as Chairman of the Board of Management since ten years. In this period revenues have been doubled and the operating loss of EUR -1.7 m has been turned in positive earnings (EBIT) of more than EUR 42 m.

Since in the meantime Biotest Group is producing its pharmaceutical products in Dreieich in Germany as well as in Boca Raton, USA, and wants to continue growing,the Supervisory Board has appointed Dr. Georg Floß to the Board of Management effective January 9, 2013. As 'Chief Operations Officer' he will be responsible for production and operations. Dr. Floß joined Biotest in February 2008 as head of production in Dreieich. In 2010/11 he was also responsible for the extension and expansion of Biotest's activities in Boca Raton, Florida, USA.

Besides Prof. Schulz and Dr. Floß, Dr. Michael Ramroth continues to be a member of the Board of Management responsible for finance and central services.

The Chairman of the Supervisory Board, Dr. Alessandro Banchi, thanked Prof. Schulz explicitly for his very successful ten year term of service as CEO and his willingness to continue as CEO till end of 2014 beyond the originally agreed term. 'With the appointment of Dr. Floß to the Board of Management we wanted to strengthen also the human management resources for continued growth of the group', emphasized Dr. Banchi.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of application of clinical immunology, haematology and intensive medicine. In its Plasma Protein portfolio Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest also researches into the development of monoclonal antibodies, including in the indications of rheumatoid arthritis and cancer of plasma cells. Biotest has more than 1.600 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart